Ebselen
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ebselen (also called PZ 51, DR3305, and SPI-1005), is a synthetic organoselenium molecule under preliminary investigation as a drug candidate. It belongs to the class of compounds related to benzene and its derivatives. It is being developed by the Seattle biotechnology company, Sound Pharmaceuticals, Inc. It has also been reported to target tubulin, blocking its polymerization. Ebselen has been entered into clinical trials as a lead compound intended for the potential treatment of various diseases. Its most advanced clinical trial is a Phase III study in people with Meniere's disease, completed in July 2024. In vitro, ebselen is a mimic of glutathione peroxidase and reacts with peroxynitrite. It is purported to have antioxidant and anti-inflammatory properties.
Ebselen (also called PZ 51, DR3305, and SPI-1005), is a synthetic organoselenium molecule under preliminary investigation as a drug candidate. It belongs to the class of compounds related to benzene and its derivatives. It is being developed by the Seattle biotechnology company, Sound Pharmaceuticals, Inc. It has also been reported to target tubulin, blocking its polymerization. Ebselen has been entered into clinical trials as a lead compound intended for the potential treatment of various diseases. Its most advanced clinical trial is a Phase III study in people with Meniere's disease, completed in July 2024. In vitro, ebselen is a mimic of glutathione peroxidase and reacts with peroxynitrite. It is purported to have antioxidant and anti-inflammatory properties.
Research
Ebselen is in preliminary clinical development for the potential treatment of hearing loss and depression, among other medical indications.
See also
List of investigational antidepressants List of investigational bipolar disorder drugs
External links
Sound Pharmaceuticals, Inc., corporate website
Text derived from https://en.wikipedia.org/w/index.php?oldid=1357686227 under CC BY-SA 4.0; modifications have been made.